We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BODITECH

Boditech Med Inc. develops products for in-vitro diagnostics and diagnostic reagents. Its products include automatic ... read more Featured Products: More products

Download Mobile App




Novel Point-Of-Care Procalcitonin Assay Performance Analyzed

By LabMedica International staff writers
Posted on 11 Dec 2019
There is a growing use of procalcitonin (PCT) measurements as a mean to diagnose and manage sepsis and PCT emerged as a useful tool to manage it accordingly, particularly in the emergency department (ED) and intensive care units (ICU).

PCT has a fair diagnostic accuracy for bacteremia in adult, neonates, infants, and children, hospitalized patients suspected of infection or sepsis. More...
Low procalcitonin levels can be used to rule out the presence of bacteremia. All commercial quantitative assays use the same ‘sandwich enzyme-linked immunosorbent assay (ELISA) principle to quantify PCT by forming antibody–procalcitonin–antibody complexes.

Scientists connected with the Hospital Center Université de Montpellier (Montpellier, France) analyzed the performance of the AFIASPCT Plus assay that was conducted using the AFIAS-6 instrument (Boditech, Dongnae-myeon, Republic of Korea). The AFIAS PCT Plus assay is a fluorescence immunoassay that quantifies PCT concentration in serum, plasma and whole blood (10–50 μL) drawn from a finger or heel using a capillary tip. The AFIAS-6 point of care (POC) assay uses an all-in-one cartridge which automates the entire procedure from sample preparation to test. PCT levels were determined using the BRAHMS PCT assay (B·R·A·H·M·S GmbH, Hennigsdorf, Germany), which is routinely used at the central laboratory.

Analytical performances including imprecision studies, limit of blank (LoB), limit of detection (LoD) and limit of quantification (LOQ) were determined. The method comparison was performed using plasma versus whole blood for the BRAHMS Kryptor CompactPlus versus AFIAS-6, respectively. The scientists reported that the total imprecision was far from the coefficient of variation (CV) of 4.5% claimed by the manufacturer and close to 10%, for levels of PCT at 0.4 and 8.3 μg/L. The LoD of this novel PCT assay was found to close to the LoD provided by the manufacturer at 0.04 μg/L. The LOQ was higher than that claimed by the manufacturer (0.1 versus 0.002, respectively). Correlation studies showed a good correlation between PCT measurements using plasma on Kryptor system and on corresponding whole blood with POC reaching a bias of −0.04 in the range from 0.02 to 2 μg/L.

The authors concluded that the novel PCT assay on AFIAS-6 is an acceptable POC alternative for the diagnosis and management of sepsis at EDs to improve the flow of patients, as results are consistent with those of the standard PCT Kryptor Compact Plus assay, despite its higher imprecision. The study was available online since October 26, 2019 in the journal Practical Laboratory Medicine.

Related Links:
Hospital Center Université de Montpellier
Boditech
B·R·A·H·M·S GmbH



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.